secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001062993-25-012044
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients
--------------------------------------------------------------------------------

- Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
- Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).
- Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.
- Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/0001062993-25-012044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-012044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer